The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas

Journal of Endocrinology

Volumn 159, Issue 2, 1998, Pages 247-255

  Yoshimoto, T ^a   Naruse, M ^a   Zeng, Z ^c   Nishikawa, T ^a   Kasajima, T ^a   Toma, H ^a   Yamamori, S ^b   Matsumoto, H ^b   Tanabe, A ^a   Naruse, K ^a   Demura, H ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Division of Genetic Research Laboratory   (Japan)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADRENAL CORTEX ADENOMA; ADULT; ARTICLE; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0031796242     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1590247     Document Type: Article

References (23)

1. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dalla Palma P & Harris AL 1996 p21WAF1 immunohistochemical expression in breast carcinoma: correlation with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alteration and relapse-free survival. British Journal of Cancer 74 208-215.
2. Buchman VL, Chumakov PM & Georgiev GP 1988 A variation in the structure of the protein-coding region of the human p53 gene. Gene 70 245-252.
3. Dahia PLM, Aguiar RCT, Tsanaclis AM, Bendit I, Bydlowski SP, Abelin NMA & Toledo SPA 1995 Molecular and immunohistochemical analysis of p53 in phaeochromocytoma. British Journal of Cancer 72 1211-1213.
4. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW & Vogelstein B 1995 Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Research 55 2910-2919.
5. Futreal PA, Barrett JC & Wiseman RW 1991 An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Research 19 6977.
6. Greenblatt MS, Bennett WP, Hollstein M & Harris CC 1994 Mutation in the p53 tumor supressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research 54 4855-4878.
7. Hall PA & Lane DP 1994 p53 in tumor pathology: can we trust immunohistochemistry? - revisited. Journal of Pathology 172 1-4.
8. Hollstein M, Sidransky D, Vogelstein B & Harris CC 1991 p53 mutations in human cancers. Science 235 49-53.
9. Khosla S, Patel VM, Hay ID, Schaid DJ, Grant CS, Van Heerden JA & Thibodeau 1991 Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. Journal of Clinical Investigation 87 1691-1699.
10. Landsberg L & Young JB 1992 Catecholamines and the adrenal medulla. In Williams Textbook of Endocrinology, edn 8, pp 621-705. Eds JD Wilson & DW Foster. Philadelphia: Saunders.
11. Lin SR, Lee YJ & Tsai JH 1994 Mutations of the p53 gene in human functional adrenal neoplasms. Journal of Clinical Endocrinology and Metabolism 78 483-491.
12. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, Chella A, Merlo G, Angeletti CA, Palma PD & Bevilacqua G 1996 p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12 1319-1324.
13. Orth DN, Kovacs WJ & DeBold CR 1992 The adrenal cortex. In Williams Textbook of Endocrinology, edn 8, pp 489-621. Eds JD Wilson & DW Foster. Philadelphia: Saunders.
14. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM & Chrousos GP 1994 p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism 78 790-794.
15. Reincke M, Wachenfeld C, Mora P, Thumser A, Jaursch-Hancke C, Abdelhamid S, Chrousos GP & Allolio B 1996 p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 'hot spot' found in Taiwan. Journal of Clinical Endocrinology and Metabolism 81 3636-3638.
16. Sambrook J, Fritsch EF & Maniatis T 1989 Molecular Cloning. A Laboratory Manual, edn 2, pp 6·30-6·31. New York: Cold Spring Harbor Laboratory Press.
17. Slebos RJ, Baas IO, Clement M, Polak M, Mulder JW, van den Berg FM, Hamilton SR & Offerhaus GJ 1996 Clinical and pathological association with p53 tumor-suppressor gene mutations and expression of p21 WAF1/CIP1 in colorectal carcinoma. British Journal of Cancer 74 165-171.
18. Velculescu VE & El-Deiry WS 1996 Biological and clinical importance of the p53 tumor supressor gene. Clinical Chemistry 42 858-868.
19. Vojtesek B, Bartek J, Midgley CA & Lane DP 1992 An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. Journal of Immunological Methods 151 237-244.
20. Wang DG, Johnston CF, Anderson N, Sloan JM & Buchanan KD 1995 Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. Journal of Pathology 175 397-401.
21. Yana I, Nakamura T, Shin E, Karakawa K, Kurahashi H, Kurita Y, Kobayashi T, Mori T, Nishisho I & Takai S 1992 Inactivation of the p53 gene is not required for tumorgenesis of medullary thyroid carcinoma or pheochromocytoma. Japanese Journal of Cancer Research 83 1113-1116.
22. Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Robertson CN, LaRocca R & Zbar B 1989 Genetic changes in human adrenocortical carcinoma. Journal of the National Cancer Institute 81 518-523.
23. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S & Itakura M 1992 Role of p53 mutations in endocrine tumorgenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Research 52 5061-5064.